JP2014510041A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014510041A5 JP2014510041A5 JP2013551271A JP2013551271A JP2014510041A5 JP 2014510041 A5 JP2014510041 A5 JP 2014510041A5 JP 2013551271 A JP2013551271 A JP 2013551271A JP 2013551271 A JP2013551271 A JP 2013551271A JP 2014510041 A5 JP2014510041 A5 JP 2014510041A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- item
- composition according
- spasm
- facial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 51
- 239000008194 pharmaceutical composition Substances 0.000 claims description 47
- 239000002105 nanoparticle Substances 0.000 claims description 45
- 210000003491 skin Anatomy 0.000 claims description 19
- 108030001720 Bontoxilysin Proteins 0.000 claims description 11
- 229940053031 botulinum toxin Drugs 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 230000037303 wrinkles Effects 0.000 claims description 11
- 208000008454 Hyperhidrosis Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 208000035475 disorder Diseases 0.000 claims description 10
- 239000003921 oil Substances 0.000 claims description 10
- 239000002245 particle Substances 0.000 claims description 10
- 239000013543 active substance Substances 0.000 claims description 9
- 229940124597 therapeutic agent Drugs 0.000 claims description 9
- 206010019233 Headaches Diseases 0.000 claims description 8
- 208000005392 Spasm Diseases 0.000 claims description 8
- 231100000869 headache Toxicity 0.000 claims description 8
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 8
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 8
- 230000035900 sweating Effects 0.000 claims description 8
- 230000001815 facial effect Effects 0.000 claims description 7
- 239000004094 surface-active agent Substances 0.000 claims description 7
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 6
- 208000008035 Back Pain Diseases 0.000 claims description 6
- 208000008238 Muscle Spasticity Diseases 0.000 claims description 6
- 206010040954 Skin wrinkling Diseases 0.000 claims description 6
- 230000002500 effect on skin Effects 0.000 claims description 6
- 239000008387 emulsifying waxe Substances 0.000 claims description 6
- 239000002480 mineral oil Substances 0.000 claims description 6
- 235000010446 mineral oil Nutrition 0.000 claims description 6
- 235000019271 petrolatum Nutrition 0.000 claims description 6
- 239000003871 white petrolatum Substances 0.000 claims description 6
- 208000014094 Dystonic disease Diseases 0.000 claims description 5
- 239000002609 medium Substances 0.000 claims description 5
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 5
- 229920000053 polysorbate 80 Polymers 0.000 claims description 5
- 229940068968 polysorbate 80 Drugs 0.000 claims description 5
- 208000018198 spasticity Diseases 0.000 claims description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 5
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 4
- 208000035985 Body Odor Diseases 0.000 claims description 4
- 201000004624 Dermatitis Diseases 0.000 claims description 4
- 206010063006 Facial spasm Diseases 0.000 claims description 4
- 208000004095 Hemifacial Spasm Diseases 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 claims description 4
- 206010040904 Skin odour abnormal Diseases 0.000 claims description 4
- 206010000496 acne Diseases 0.000 claims description 4
- 208000010118 dystonia Diseases 0.000 claims description 4
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 4
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 4
- 229960002216 methylparaben Drugs 0.000 claims description 4
- 208000004296 neuralgia Diseases 0.000 claims description 4
- 230000000149 penetrating effect Effects 0.000 claims description 4
- 229920000136 polysorbate Polymers 0.000 claims description 4
- 229950008882 polysorbate Drugs 0.000 claims description 4
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 4
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 4
- 229960003415 propylparaben Drugs 0.000 claims description 4
- 210000002307 prostate Anatomy 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 4
- 208000007101 Muscle Cramp Diseases 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 210000005070 sphincter Anatomy 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 201000004384 Alopecia Diseases 0.000 claims description 2
- 206010002153 Anal fissure Diseases 0.000 claims description 2
- 208000016583 Anus disease Diseases 0.000 claims description 2
- 206010003591 Ataxia Diseases 0.000 claims description 2
- 208000035143 Bacterial infection Diseases 0.000 claims description 2
- 206010069632 Bladder dysfunction Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 208000005872 Diffuse Esophageal Spasm Diseases 0.000 claims description 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 2
- 206010013774 Dry eye Diseases 0.000 claims description 2
- 201000011275 Epicondylitis Diseases 0.000 claims description 2
- 208000000289 Esophageal Achalasia Diseases 0.000 claims description 2
- 208000004929 Facial Paralysis Diseases 0.000 claims description 2
- 206010016228 Fasciitis Diseases 0.000 claims description 2
- 208000009531 Fissure in Ano Diseases 0.000 claims description 2
- 206010017533 Fungal infection Diseases 0.000 claims description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 2
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims description 2
- 208000021710 Hyperpigmentation disease Diseases 0.000 claims description 2
- 206010020853 Hypertonic bladder Diseases 0.000 claims description 2
- 208000026748 Hypopigmentation disease Diseases 0.000 claims description 2
- 208000003351 Melanosis Diseases 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- 208000031888 Mycoses Diseases 0.000 claims description 2
- 206010028836 Neck pain Diseases 0.000 claims description 2
- 206010030136 Oesophageal achalasia Diseases 0.000 claims description 2
- 206010030184 Oesophageal spasm Diseases 0.000 claims description 2
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000036496 Pelvic floor dyssynergia Diseases 0.000 claims description 2
- 208000003251 Pruritus Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 208000012322 Raynaud phenomenon Diseases 0.000 claims description 2
- 208000005793 Restless legs syndrome Diseases 0.000 claims description 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 2
- 241001303601 Rosacea Species 0.000 claims description 2
- 206010039792 Seborrhoea Diseases 0.000 claims description 2
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 206010067672 Spasmodic dysphonia Diseases 0.000 claims description 2
- 208000004350 Strabismus Diseases 0.000 claims description 2
- 208000002240 Tennis Elbow Diseases 0.000 claims description 2
- 206010043269 Tension headache Diseases 0.000 claims description 2
- 208000008548 Tension-Type Headache Diseases 0.000 claims description 2
- 206010044074 Torticollis Diseases 0.000 claims description 2
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 2
- 208000016620 Tourette disease Diseases 0.000 claims description 2
- 206010044565 Tremor Diseases 0.000 claims description 2
- 208000036826 VIIth nerve paralysis Diseases 0.000 claims description 2
- 206010047642 Vitiligo Diseases 0.000 claims description 2
- 201000000621 achalasia Diseases 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 208000009621 actinic keratosis Diseases 0.000 claims description 2
- 201000010105 allergic rhinitis Diseases 0.000 claims description 2
- 201000002898 anismus Diseases 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
- 206010006514 bruxism Diseases 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 206010008129 cerebral palsy Diseases 0.000 claims description 2
- 201000002866 cervical dystonia Diseases 0.000 claims description 2
- 239000002612 dispersion medium Substances 0.000 claims description 2
- 238000001849 endotracheal instillation Methods 0.000 claims description 2
- 201000006517 essential tremor Diseases 0.000 claims description 2
- 210000004709 eyebrow Anatomy 0.000 claims description 2
- 230000008921 facial expression Effects 0.000 claims description 2
- 208000014337 facial nerve disease Diseases 0.000 claims description 2
- 210000001061 forehead Anatomy 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 210000004907 gland Anatomy 0.000 claims description 2
- 210000003780 hair follicle Anatomy 0.000 claims description 2
- 208000024963 hair loss Diseases 0.000 claims description 2
- 230000003676 hair loss Effects 0.000 claims description 2
- 230000037315 hyperhidrosis Effects 0.000 claims description 2
- 206010020718 hyperplasia Diseases 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 claims description 2
- 238000001361 intraarterial administration Methods 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 238000007913 intrathecal administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 238000007914 intraventricular administration Methods 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 210000001352 masseter muscle Anatomy 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 210000003205 muscle Anatomy 0.000 claims description 2
- 208000018360 neuromuscular disease Diseases 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 208000020629 overactive bladder Diseases 0.000 claims description 2
- 239000011148 porous material Substances 0.000 claims description 2
- 208000017497 prostate disease Diseases 0.000 claims description 2
- 206010039083 rhinitis Diseases 0.000 claims description 2
- 201000004700 rosacea Diseases 0.000 claims description 2
- 210000001732 sebaceous gland Anatomy 0.000 claims description 2
- 210000002374 sebum Anatomy 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 201000010106 skin squamous cell carcinoma Diseases 0.000 claims description 2
- 201000002849 spasmodic dystonia Diseases 0.000 claims description 2
- 210000000434 stratum corneum Anatomy 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 210000000106 sweat gland Anatomy 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 210000001738 temporomandibular joint Anatomy 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 206010044652 trigeminal neuralgia Diseases 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 230000007774 longterm Effects 0.000 claims 3
- 239000003623 enhancer Substances 0.000 claims 2
- 238000011200 topical administration Methods 0.000 claims 2
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 208000037845 Cutaneous squamous cell carcinoma Diseases 0.000 claims 1
- 208000008930 Low Back Pain Diseases 0.000 claims 1
- 208000007542 Paresis Diseases 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 208000013142 Writer cramp Diseases 0.000 claims 1
- -1 antibody Proteins 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 210000000744 eyelid Anatomy 0.000 claims 1
- 201000002865 focal hand dystonia Diseases 0.000 claims 1
- 239000007972 injectable composition Substances 0.000 claims 1
- 239000008297 liquid dosage form Substances 0.000 claims 1
- 210000004237 neck muscle Anatomy 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 230000037368 penetrate the skin Effects 0.000 claims 1
- 201000004240 prostatic hypertrophy Diseases 0.000 claims 1
- 239000006210 lotion Substances 0.000 description 28
- 238000000034 method Methods 0.000 description 16
- 230000037371 chromhidrosis Effects 0.000 description 2
- 208000015318 chromhidrosis Diseases 0.000 description 2
- 239000003961 penetration enhancing agent Substances 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- 206010028311 Muscle hypertrophy Diseases 0.000 description 1
- 206010051482 Prostatomegaly Diseases 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 206010005159 blepharospasm Diseases 0.000 description 1
- 230000000744 blepharospasm Effects 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000012042 muscle hypertrophy Effects 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 208000020352 skin basal cell carcinoma Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161435778P | 2011-01-24 | 2011-01-24 | |
| US61/435,778 | 2011-01-24 | ||
| PCT/US2012/022279 WO2012103038A2 (en) | 2011-01-24 | 2012-01-23 | Nanoparticle compositions, formulations thereof, and uses therefor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016054872A Division JP2016117765A (ja) | 2011-01-24 | 2016-03-18 | ナノ粒子組成物、その製剤およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014510041A JP2014510041A (ja) | 2014-04-24 |
| JP2014510041A5 true JP2014510041A5 (enExample) | 2015-03-12 |
| JP5943258B2 JP5943258B2 (ja) | 2016-07-05 |
Family
ID=45554904
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013551271A Active JP5943258B2 (ja) | 2011-01-24 | 2012-01-23 | ナノ粒子組成物、その製剤およびその使用 |
| JP2016054872A Pending JP2016117765A (ja) | 2011-01-24 | 2016-03-18 | ナノ粒子組成物、その製剤およびその使用 |
| JP2017207274A Active JP6596475B2 (ja) | 2011-01-24 | 2017-10-26 | ナノ粒子組成物、その製剤およびその使用 |
| JP2019125459A Active JP7166992B2 (ja) | 2011-01-24 | 2019-07-04 | ナノ粒子組成物、その製剤およびその使用 |
| JP2021055533A Pending JP2021105015A (ja) | 2011-01-24 | 2021-03-29 | ナノ粒子組成物、その製剤およびその使用 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016054872A Pending JP2016117765A (ja) | 2011-01-24 | 2016-03-18 | ナノ粒子組成物、その製剤およびその使用 |
| JP2017207274A Active JP6596475B2 (ja) | 2011-01-24 | 2017-10-26 | ナノ粒子組成物、その製剤およびその使用 |
| JP2019125459A Active JP7166992B2 (ja) | 2011-01-24 | 2019-07-04 | ナノ粒子組成物、その製剤およびその使用 |
| JP2021055533A Pending JP2021105015A (ja) | 2011-01-24 | 2021-03-29 | ナノ粒子組成物、その製剤およびその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US20120328701A1 (enExample) |
| EP (2) | EP2667859A2 (enExample) |
| JP (5) | JP5943258B2 (enExample) |
| KR (5) | KR20140005998A (enExample) |
| CN (2) | CN103596559A (enExample) |
| AU (4) | AU2012209274A1 (enExample) |
| BR (1) | BR112013018920A2 (enExample) |
| IL (3) | IL313839A (enExample) |
| SG (2) | SG10201804552WA (enExample) |
| WO (1) | WO2012103038A2 (enExample) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100266638A1 (en) | 2004-02-26 | 2010-10-21 | Allergan, Inc. | Headache treatment method |
| US9486408B2 (en) * | 2005-12-01 | 2016-11-08 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
| CA2671133C (en) | 2006-12-01 | 2015-11-24 | Anterios, Inc. | Peptide nanoparticles and uses therefor |
| EP2494958A1 (en) | 2006-12-01 | 2012-09-05 | Anterios, Inc. | Amphiphilic Entity Nanoparticles |
| US10016451B2 (en) | 2007-05-31 | 2018-07-10 | Anterios, Inc. | Nucleic acid nanoparticles and uses therefor |
| CA2696570C (en) | 2007-08-17 | 2020-12-29 | Novartis Ag | Cyclic depsipeptides |
| WO2012103035A1 (en) * | 2011-01-24 | 2012-08-02 | Anterios, Inc. | Nanoparticle compositions |
| US8680054B2 (en) | 2011-04-20 | 2014-03-25 | Novartis Ag | Suspension type topical formulations comprising cyclic depsipeptide |
| AR086168A1 (es) | 2011-04-20 | 2013-11-27 | Novartis Ag | Procesos para la elaboracion de depsipeptidos macrociclicos e intermediarios |
| US20140051637A1 (en) * | 2011-04-28 | 2014-02-20 | National University Corporation Nagoya University | Brain-targeting functional nucleic acid and use thereof |
| US9849512B2 (en) | 2011-07-01 | 2017-12-26 | Attostat, Inc. | Method and apparatus for production of uniformly sized nanoparticles |
| US10016473B2 (en) | 2012-08-17 | 2018-07-10 | Howard University | Method, apparatus, and kit for the pulsing treatment of neurodegenerative diseases and impairments |
| US9101652B2 (en) | 2012-08-17 | 2015-08-11 | Howard University | Method, apparatus and kit for the treatment of neurodegenerative diseases and impairments |
| US9012490B2 (en) | 2012-08-17 | 2015-04-21 | Howard University | Lipophilic curcumin analogs and methods of inhibiting HIV-1, treating latent HIV in the brain, and preventing HIV-mediated cognitive decline and HIV dementia |
| US9067978B2 (en) | 2012-10-09 | 2015-06-30 | Novartis Ag | Solution phase processes for the manufacture of macrocyclic depsipeptides and new intermediates |
| US8987413B2 (en) | 2012-10-09 | 2015-03-24 | Novartis Ag | Aldehyde acetal based processes for the manufacture of macrocyclic depsipeptides and new intermediates |
| WO2014117070A1 (en) * | 2013-01-25 | 2014-07-31 | Nwulia Evaristus A | Curcumin analogs and methods of inhibiting hiv-1 |
| EP2964763B1 (en) * | 2013-03-08 | 2019-09-18 | Yale University | Compositions and methods for reducing skin pigmentation |
| EP3065717A1 (en) | 2013-11-04 | 2016-09-14 | Biopharmx, Inc. | Dosage form comprising an active ingredient and a plurality of solid porous microcarriers |
| EP4241771A3 (en) * | 2013-11-08 | 2023-11-22 | Antivirus Therapeutics | Methods and compositions for treating sepsis |
| CA2933579A1 (en) | 2013-12-11 | 2015-06-18 | University Of Massachusetts | Compositions and methods for treating disease using salmonella t3ss effector protein (sipa) |
| KR101478520B1 (ko) * | 2014-01-24 | 2015-01-02 | 동신대학교산학협력단 | 피부 안전성이 향상된 캡사이신-펩타이드 및 이를 이용한 피부 외용제 조성물 |
| AU2015252947B2 (en) * | 2014-05-01 | 2020-07-09 | Anterios, Inc. | Demonstrable efficacy across or within patient populations |
| KR20230042391A (ko) * | 2014-10-03 | 2023-03-28 | 나노틱스 엘엘씨 | 가용성 생물분자의 생물학적 활성을 억제하기 위한 조성물 및 방법 |
| KR20170134514A (ko) | 2015-03-23 | 2017-12-06 | 바이오팜엑스 인코포레이티드 | 피부과 사용을 위한 약학 테트라사이클린 조성물 |
| WO2016161348A1 (en) | 2015-04-01 | 2016-10-06 | Attostat, Inc. | Nanoparticle compositions and methods for treating or preventing tissue infections and diseases |
| US10774429B2 (en) * | 2015-04-13 | 2020-09-15 | Attostat, Inc. | Anti-corrosion nanoparticle compositions |
| US11473202B2 (en) | 2015-04-13 | 2022-10-18 | Attostat, Inc. | Anti-corrosion nanoparticle compositions |
| US11617724B2 (en) * | 2015-05-21 | 2023-04-04 | Dermavant Sciences GmbH | Topical pharmaceutical compositions |
| ES2596720B1 (es) * | 2015-07-10 | 2018-01-29 | Juvilis Cosmetics S.L. | Composiciones para uso tópico |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| US9931349B2 (en) | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| HUE046449T2 (hu) | 2016-09-13 | 2020-03-30 | Allergan Inc | Stabilizált, nem fehérje eredetû, clostridiális toxin készítmények |
| US11311496B2 (en) | 2016-11-21 | 2022-04-26 | Eirion Therapeutics, Inc. | Transdermal delivery of large agents |
| WO2018236876A2 (en) * | 2017-06-19 | 2018-12-27 | Washington University | Nanoemulsion and methods of use thereof |
| DK3431072T3 (da) | 2017-07-17 | 2020-02-17 | Dr August Wolff Gmbh & Co Kg Arzneimittel | Olie-i-vand-emulsion |
| JP2020529994A (ja) | 2017-07-31 | 2020-10-15 | ジャニュアリー セラピューティクス，インク． | 有機リン酸誘導体 |
| US11646453B2 (en) | 2017-11-28 | 2023-05-09 | Attostat, Inc. | Nanoparticle compositions and methods for enhancing lead-acid batteries |
| US11018376B2 (en) | 2017-11-28 | 2021-05-25 | Attostat, Inc. | Nanoparticle compositions and methods for enhancing lead-acid batteries |
| WO2019113475A1 (en) * | 2017-12-07 | 2019-06-13 | Dermavant Sciences GmbH | Topical ointment formulations and their use in treating skin conditions |
| GB201721840D0 (en) * | 2017-12-22 | 2018-02-07 | Waterford Institute Of Tech | Microemulsion for opthalmic drug delivery |
| EP3758490A4 (en) * | 2018-03-02 | 2021-12-22 | January Therapeutics, Inc. | COMPOSITIONS OF NANOPARTICLES |
| US12138301B2 (en) * | 2018-03-02 | 2024-11-12 | Elicio Therapeutics, Inc. | Compounds including a mutant KRAS sequence and a lipid and uses thereof |
| IL277101B2 (en) * | 2018-03-02 | 2024-09-01 | Elicio Therapeutics Inc | Cpg amphiphiles and uses thereof |
| WO2020056191A1 (en) | 2018-09-13 | 2020-03-19 | Eirion Therapeutics, Inc. | Uses of plasminogen activator inhibitor 1 (pai-1) inhibitors |
| EP3849539A1 (en) | 2018-09-13 | 2021-07-21 | Eirion Therapeutics, Inc. | Plasminogen activator inhibitor 1 (pai-1) inhibitors and uses therefor |
| AU2019391791A1 (en) | 2018-12-03 | 2021-06-03 | Eirion Therapeutics, Inc. | Improved delivery of large agents |
| US20220273765A1 (en) * | 2019-04-24 | 2022-09-01 | Follicum Ab | Topical formulation |
| JP2022533113A (ja) | 2019-05-14 | 2022-07-21 | エイリオン セラピューティクス， インコーポレイテッド | ピーク効果の遅延および／または応答持続時間の延長 |
| US12115250B2 (en) | 2019-07-12 | 2024-10-15 | Evoq Nano, Inc. | Use of nanoparticles for treating respiratory infections associated with cystic fibrosis |
| US11708637B2 (en) | 2019-08-13 | 2023-07-25 | The Regents Of The University Of California | Methods of supporting a graphene sheet disposed on a frame support |
| DE102019215585B4 (de) * | 2019-10-10 | 2022-02-17 | KCM Egészségügyi és Tudományos Korlátolt Felelösségü Társaság | Verfahren zur prävention von strahlenschäden in humanen drüsen |
| US12280096B2 (en) | 2021-07-12 | 2025-04-22 | Penland Foundation | Treatments of cancer using nitrous oxide and botulinum toxin |
| US12456759B2 (en) | 2021-03-30 | 2025-10-28 | Evoq Nano, Inc. | Nanoparticle-enhanced lead-acid electrode paste and improved lead-acid batteries made therefrom |
| JP2024543050A (ja) * | 2021-11-24 | 2024-11-19 | ジェニビジョン インコーポレイテッド | 脳及び中枢神経系の疾患を治療するための送達方法 |
| WO2024150216A1 (en) * | 2023-01-09 | 2024-07-18 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Topical compositions and methods for treating alopecia |
| WO2025064449A1 (en) | 2023-09-18 | 2025-03-27 | Eirion Therapeutics, Inc. | Topical compositions and uses of pai-1 inhibitors |
| WO2025165954A1 (en) * | 2024-01-30 | 2025-08-07 | The University Of North Carolina At Chapel Hill | Lipid nanoemulsion formulations for contrast agents and methods of using the same |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US296006A (en) | 1884-04-01 | John hoefleb | ||
| DE2929425A1 (de) * | 1979-07-20 | 1981-02-12 | Lothar Kling | Vorrichtung fuer injektionsspritzen zur intramuskulaeren und subentanen injektion |
| US4270537A (en) | 1979-11-19 | 1981-06-02 | Romaine Richard A | Automatic hypodermic syringe |
| US4908154A (en) | 1981-04-17 | 1990-03-13 | Biotechnology Development Corporation | Method of forming a microemulsion |
| US4533254A (en) | 1981-04-17 | 1985-08-06 | Biotechnology Development Corporation | Apparatus for forming emulsions |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
| US4886499A (en) | 1986-12-18 | 1989-12-12 | Hoffmann-La Roche Inc. | Portable injection appliance |
| GB8704027D0 (en) | 1987-02-20 | 1987-03-25 | Owen Mumford Ltd | Syringe needle combination |
| US4940460A (en) | 1987-06-19 | 1990-07-10 | Bioject, Inc. | Patient-fillable and non-invasive hypodermic injection device assembly |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US5339163A (en) | 1988-03-16 | 1994-08-16 | Canon Kabushiki Kaisha | Automatic exposure control device using plural image plane detection areas |
| FR2638359A1 (fr) | 1988-11-03 | 1990-05-04 | Tino Dalto | Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau |
| US5008110A (en) | 1988-11-10 | 1991-04-16 | The Procter & Gamble Company | Storage-stable transdermal patch |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US6005087A (en) | 1995-06-06 | 1999-12-21 | Isis Pharmaceuticals, Inc. | 2'-modified oligonucleotides |
| US6399754B1 (en) | 1991-12-24 | 2002-06-04 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides |
| US5190521A (en) | 1990-08-22 | 1993-03-02 | Tecnol Medical Products, Inc. | Apparatus and method for raising a skin wheal and anesthetizing skin |
| US6165500A (en) | 1990-08-24 | 2000-12-26 | Idea Ag | Preparation for the application of agents in mini-droplets |
| US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
| GB9118204D0 (en) | 1991-08-23 | 1991-10-09 | Weston Terence E | Needle-less injector |
| SE9102652D0 (sv) | 1991-09-13 | 1991-09-13 | Kabi Pharmacia Ab | Injection needle arrangement |
| US6939852B2 (en) | 1991-09-24 | 2005-09-06 | Allergan, Inc. | Methods and compositions for the treatment of cerebral palsy |
| US7384918B2 (en) | 1991-09-24 | 2008-06-10 | Allergan, Inc. | Botulinum toxin for treating muscle contracture |
| US5613952A (en) * | 1991-12-23 | 1997-03-25 | Syringe Develpoment Partners | Safety syringe |
| US5328483A (en) | 1992-02-27 | 1994-07-12 | Jacoby Richard M | Intradermal injection device with medication and needle guard |
| US6010715A (en) | 1992-04-01 | 2000-01-04 | Bertek, Inc. | Transdermal patch incorporating a polymer film incorporated with an active agent |
| CA2138020C (en) * | 1992-06-23 | 1999-02-16 | Eric A. Johnson | Pharmaceutical composition containing botulinum b complex |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US5569189A (en) | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
| US5334144A (en) | 1992-10-30 | 1994-08-02 | Becton, Dickinson And Company | Single use disposable needleless injector |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1261849B (it) | 1993-09-02 | 1996-06-03 | Avantgarde Spa | Dispositivo medico per la somministrazione di principi attivi o farmaci a bassissimo dosaggio, in particolare di farmaci omeopatici. |
| US5798340A (en) | 1993-09-17 | 1998-08-25 | Gilead Sciences, Inc. | Nucleotide analogs |
| WO1995024176A1 (en) | 1994-03-07 | 1995-09-14 | Bioject, Inc. | Ampule filling device |
| US5466220A (en) | 1994-03-08 | 1995-11-14 | Bioject, Inc. | Drug vial mixing and transfer device |
| US5596091A (en) | 1994-03-18 | 1997-01-21 | The Regents Of The University Of California | Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides |
| US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
| US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
| DE69627963T2 (de) * | 1995-06-06 | 2004-03-04 | Pearce, L. Bruce, Cambridge | Verbesserte zusammensetzungen und verfahren zur chemodenervation mit neurotoxinen |
| US5893397A (en) | 1996-01-12 | 1999-04-13 | Bioject Inc. | Medication vial/syringe liquid-transfer apparatus |
| GB9607549D0 (en) | 1996-04-11 | 1996-06-12 | Weston Medical Ltd | Spring-powered dispensing device |
| US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
| US6127533A (en) | 1997-02-14 | 2000-10-03 | Isis Pharmaceuticals, Inc. | 2'-O-aminooxy-modified oligonucleotides |
| US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
| US5948433A (en) | 1997-08-21 | 1999-09-07 | Bertek, Inc. | Transdermal patch |
| IT1298087B1 (it) | 1998-01-08 | 1999-12-20 | Fiderm S R L | Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni |
| US5965154A (en) | 1998-03-17 | 1999-10-12 | Plc Holding, L.L.C. | Adhesive matrix type transdermal patch and method of manufacturing same |
| TW574036B (en) * | 1998-09-11 | 2004-02-01 | Elan Pharm Inc | Stable liquid compositions of botulinum toxin |
| US6403779B1 (en) | 1999-01-08 | 2002-06-11 | Isis Pharmaceuticals, Inc. | Regioselective synthesis of 2′-O-modified nucleosides |
| US8202979B2 (en) | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
| US20050020525A1 (en) | 2002-02-20 | 2005-01-27 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| US20050032733A1 (en) | 2001-05-18 | 2005-02-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA) |
| FR2805761B1 (fr) * | 2000-03-02 | 2002-08-30 | Mainelab | Nanocapsules lipidiques, procede de preparation et utilisation comme medicament |
| US20030175950A1 (en) | 2001-05-29 | 2003-09-18 | Mcswiggen James A. | RNA interference mediated inhibition of HIV gene expression using short interfering RNA |
| EP2390328A1 (en) | 2001-09-28 | 2011-11-30 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | MicroRNA molecules |
| US7763663B2 (en) | 2001-12-19 | 2010-07-27 | University Of Massachusetts | Polysaccharide-containing block copolymer particles and uses thereof |
| WO2003105780A2 (en) | 2002-06-18 | 2003-12-24 | Epigenesis Pharmaceuticals, Inc. | A dry powder oligonucleotide formulation, preparation and its uses |
| US20040009180A1 (en) | 2002-07-11 | 2004-01-15 | Allergan, Inc. | Transdermal botulinum toxin compositions |
| US20050013850A1 (en) * | 2003-07-15 | 2005-01-20 | Caers Jan K. | Device to assist hyperhydrosis therapy |
| US7160699B2 (en) * | 2003-09-25 | 2007-01-09 | Allergan, Inc. | Media for clostridium bacterium and processes for obtaining a clostridial toxin |
| US8734810B2 (en) * | 2003-10-29 | 2014-05-27 | Allergan, Inc. | Botulinum toxin treatments of neurological and neuropsychiatric disorders |
| JP2008513513A (ja) * | 2004-09-21 | 2008-05-01 | アネシヴァ， インコーポレイテッド | ポリヌクレオチドの送達 |
| CN103315954A (zh) | 2005-07-18 | 2013-09-25 | 麻萨诸塞州洛厄尔大学 | 制备与使用纳米乳剂的组合物和方法 |
| TR201901443T4 (tr) | 2005-12-01 | 2019-02-21 | Univ Massachusetts Lowell | Botulinum nanoemülsiyonları. |
| CA2671133C (en) | 2006-12-01 | 2015-11-24 | Anterios, Inc. | Peptide nanoparticles and uses therefor |
| EP2494958A1 (en) * | 2006-12-01 | 2012-09-05 | Anterios, Inc. | Amphiphilic Entity Nanoparticles |
| EP1938801A1 (en) * | 2006-12-22 | 2008-07-02 | Biofrontera Bioscience GmbH | Nanoemulsion |
| US10016451B2 (en) * | 2007-05-31 | 2018-07-10 | Anterios, Inc. | Nucleic acid nanoparticles and uses therefor |
| KR20160130519A (ko) * | 2008-06-26 | 2016-11-11 | 안테리오스, 인코퍼레이티드 | 경피 운반 |
-
2012
- 2012-01-23 WO PCT/US2012/022279 patent/WO2012103038A2/en not_active Ceased
- 2012-01-23 KR KR1020137022344A patent/KR20140005998A/ko not_active Ceased
- 2012-01-23 EP EP12701658.2A patent/EP2667859A2/en not_active Withdrawn
- 2012-01-23 SG SG10201804552WA patent/SG10201804552WA/en unknown
- 2012-01-23 AU AU2012209274A patent/AU2012209274A1/en not_active Abandoned
- 2012-01-23 KR KR1020207011221A patent/KR20200044145A/ko not_active Ceased
- 2012-01-23 BR BR112013018920A patent/BR112013018920A2/pt not_active Application Discontinuation
- 2012-01-23 KR KR1020247025398A patent/KR20240119180A/ko active Pending
- 2012-01-23 IL IL313839A patent/IL313839A/en unknown
- 2012-01-23 KR KR1020197002754A patent/KR20190014125A/ko not_active Ceased
- 2012-01-23 CN CN201280014362.5A patent/CN103596559A/zh active Pending
- 2012-01-23 SG SG2013072533A patent/SG193972A1/en unknown
- 2012-01-23 JP JP2013551271A patent/JP5943258B2/ja active Active
- 2012-01-23 US US13/356,617 patent/US20120328701A1/en not_active Abandoned
- 2012-01-23 EP EP19214236.2A patent/EP3689331A1/en active Pending
- 2012-01-23 CN CN201710063957.4A patent/CN106924216A/zh active Pending
- 2012-01-23 KR KR1020227045438A patent/KR20230007537A/ko not_active Ceased
- 2012-01-23 IL IL293156A patent/IL293156A/en unknown
-
2013
- 2013-07-24 IL IL227625A patent/IL227625A0/en unknown
-
2016
- 2016-03-18 JP JP2016054872A patent/JP2016117765A/ja active Pending
-
2017
- 2017-04-12 AU AU2017202440A patent/AU2017202440A1/en not_active Abandoned
- 2017-10-26 JP JP2017207274A patent/JP6596475B2/ja active Active
-
2018
- 2018-10-18 US US16/164,395 patent/US20190183785A1/en not_active Abandoned
-
2019
- 2019-02-26 AU AU2019201316A patent/AU2019201316A1/en not_active Abandoned
- 2019-07-04 JP JP2019125459A patent/JP7166992B2/ja active Active
-
2021
- 2021-01-07 AU AU2021200081A patent/AU2021200081A1/en not_active Abandoned
- 2021-03-29 JP JP2021055533A patent/JP2021105015A/ja active Pending
-
2022
- 2022-03-28 US US17/706,224 patent/US20220387299A1/en not_active Abandoned
-
2024
- 2024-08-14 US US18/805,119 patent/US20250241848A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014510041A5 (enExample) | ||
| JP2016117765A5 (enExample) | ||
| JP2014528900A5 (enExample) | ||
| JP6523843B2 (ja) | ボツリヌス菌ナノエマルジョン | |
| JP2014503585A5 (enExample) | ||
| US20170181952A1 (en) | Botulinum nanoemulsions | |
| JP2014503587A (ja) | 界面活性剤組成物 | |
| JP2014507420A (ja) | パラベン組成物 | |
| CN104602703A (zh) | 使用局部化学性去神经支配剂处理皱纹的方法 | |
| JP2007538010A (ja) | フィコトキシンの経皮投与 | |
| KR101248520B1 (ko) | 수정분말이 포함된 크림 화장품 조성물 | |
| Sameera et al. | BOTOX-A COMPREHENSIVE REVIEW AND ITS USES IN DENTISTRY | |
| Vedamurthy | Mesotherapy in Aesthetic Medicine | |
| Wu et al. | Botulinum toxin for skin rejuvenation | |
| Khan | Frontalis Injection with Botox | |
| JP2004189639A (ja) | 乳化組成物 | |
| HK1234672A1 (en) | Botulinum nanoemulsions | |
| Keys | Frontalis Injection with Botox | |
| Woodward et al. | Oculofacial Anesthesia | |
| HK1252485B (en) | Botulinum nanoemulsions | |
| AU2016202744A1 (en) | Botulinum nanoemulsions | |
| HK1124248B (en) | Botulinum nanoemulsions | |
| HK1200016B (zh) | 肉毒杆菌纳米乳液 | |
| AU2013234398A1 (en) | Botulinum nanoemulsions |